Clinical Commissioning Urgent Policy Statement: Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies

25/11/2020

Pharmacogenomic testing for DPYD polymorphisms which cause dihydropyrimidine dehydrogenase (DPD) deficiency is recommended to be available through routine commissioning as a pre-treatment screening test prior to the administration of fluoropyrimidine-based therapies through routine commissioning within the criteria set out in this document.

Clinical Commissioning Urgent Policy Statement: Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies

Tel: 07989 595237

ADDRESS

Registered Address:

1 Market Hill, Calne, Wiltshire SN11 0BT

Company Number: 12023096

OPENING HOURS

Monday - Friday: 9:00am - 5:00pm   

SUBSCRIBE TO JOIN OUR MAILING LIST

© 2019 by The Governance Academy